In preclinical studies, PARP1 inhibitors have been reported to have therapeutic potential as treatment for cardiovascular diseases and Alzheimer’s disease, and as chemotherapeutic agents that may prevent unwanted necrosis23, 80. Here, PARP1 is linked to early-onset autosomal dominant Alzheimer disease.